Cargando…

Multi-objective de novo drug design with conditional graph generative model

Recently, deep generative models have revealed itself as a promising way of performing de novo molecule design. However, previous research has focused mainly on generating SMILES strings instead of molecular graphs. Although available, current graph generative models are are often too general and co...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yibo, Zhang, Liangren, Liu, Zhenming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057868/
https://www.ncbi.nlm.nih.gov/pubmed/30043127
http://dx.doi.org/10.1186/s13321-018-0287-6
_version_ 1783341591411294208
author Li, Yibo
Zhang, Liangren
Liu, Zhenming
author_facet Li, Yibo
Zhang, Liangren
Liu, Zhenming
author_sort Li, Yibo
collection PubMed
description Recently, deep generative models have revealed itself as a promising way of performing de novo molecule design. However, previous research has focused mainly on generating SMILES strings instead of molecular graphs. Although available, current graph generative models are are often too general and computationally expensive. In this work, a new de novo molecular design framework is proposed based on a type of sequential graph generators that do not use atom level recurrent units. Compared with previous graph generative models, the proposed method is much more tuned for molecule generation and has been scaled up to cover significantly larger molecules in the ChEMBL database. It is shown that the graph-based model outperforms SMILES based models in a variety of metrics, especially in the rate of valid outputs. For the application of drug design tasks, conditional graph generative model is employed. This method offers highe flexibility and is suitable for generation based on multiple objectives. The results have demonstrated that this approach can be effectively applied to solve several drug design problems, including the generation of compounds containing a given scaffold, compounds with specific drug-likeness and synthetic accessibility requirements, as well as dual inhibitors against JNK3 and GSK-3β. [Image: see text] ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13321-018-0287-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6057868
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-60578682018-08-09 Multi-objective de novo drug design with conditional graph generative model Li, Yibo Zhang, Liangren Liu, Zhenming J Cheminform Research Article Recently, deep generative models have revealed itself as a promising way of performing de novo molecule design. However, previous research has focused mainly on generating SMILES strings instead of molecular graphs. Although available, current graph generative models are are often too general and computationally expensive. In this work, a new de novo molecular design framework is proposed based on a type of sequential graph generators that do not use atom level recurrent units. Compared with previous graph generative models, the proposed method is much more tuned for molecule generation and has been scaled up to cover significantly larger molecules in the ChEMBL database. It is shown that the graph-based model outperforms SMILES based models in a variety of metrics, especially in the rate of valid outputs. For the application of drug design tasks, conditional graph generative model is employed. This method offers highe flexibility and is suitable for generation based on multiple objectives. The results have demonstrated that this approach can be effectively applied to solve several drug design problems, including the generation of compounds containing a given scaffold, compounds with specific drug-likeness and synthetic accessibility requirements, as well as dual inhibitors against JNK3 and GSK-3β. [Image: see text] ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13321-018-0287-6) contains supplementary material, which is available to authorized users. Springer International Publishing 2018-07-24 /pmc/articles/PMC6057868/ /pubmed/30043127 http://dx.doi.org/10.1186/s13321-018-0287-6 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Li, Yibo
Zhang, Liangren
Liu, Zhenming
Multi-objective de novo drug design with conditional graph generative model
title Multi-objective de novo drug design with conditional graph generative model
title_full Multi-objective de novo drug design with conditional graph generative model
title_fullStr Multi-objective de novo drug design with conditional graph generative model
title_full_unstemmed Multi-objective de novo drug design with conditional graph generative model
title_short Multi-objective de novo drug design with conditional graph generative model
title_sort multi-objective de novo drug design with conditional graph generative model
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057868/
https://www.ncbi.nlm.nih.gov/pubmed/30043127
http://dx.doi.org/10.1186/s13321-018-0287-6
work_keys_str_mv AT liyibo multiobjectivedenovodrugdesignwithconditionalgraphgenerativemodel
AT zhangliangren multiobjectivedenovodrugdesignwithconditionalgraphgenerativemodel
AT liuzhenming multiobjectivedenovodrugdesignwithconditionalgraphgenerativemodel